The latest research on Myriad Genetics trims the modeled fair value only slightly, from US$8.32 to US$8.12 per share, and aligns a new US$7 price target with expectations across the broader ...
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 2.5% in the afternoon session after the company announced it would present new data from eight studies at the 2025 San Antonio ...
Fintel reports that on November 11, 2025, Piper Sandler maintained coverage of Myriad Genetics (NasdaqGS:MYGN) with a Overweight recommendation. As of November 9, 2025, the average one-year price ...
Myriad Genetics (NASDAQ:MYGN) is set to give its latest quarterly earnings report on Monday, 2025-11-03. Here's what investors need to know before the announcement. Analysts estimate that Myriad ...
For the quarter ended September 2025, Myriad Genetics (MYGN) reported revenue of $205.7 million, down 3.6% over the same period last year. EPS came in at $0, compared to $0.06 in the year-ago quarter.
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 3.7% in the afternoon session after the company signed an exclusive agreement with Zydus Lifesciences to commercialize a trio of ...